Status:

RECRUITING

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

Lead Sponsor:

University Hospital, Bordeaux

Conditions:

Myeloproliferative Neoplasm

Eligibility:

All Genders

18+ years

Brief Summary

Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive di...

Detailed Description

Myeloproliferative Neoplasia (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. They include Essential Thrombocythemia (ET), Polycythemia Vera (VP) and Pr...

Eligibility Criteria

Inclusion

  • For the 110 patients with MPN:
  • Patients with PV, ET or PMF
  • DNA extracted from purified granulocytes at time of diagnosis
  • No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)
  • For the 10 subjects without MPN:
  • Absence of hematological malignancy
  • Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia
  • Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)

Exclusion

  • For the 110 patients with MPN:
  • Patients without PV, ET or PMF
  • Patients without purified granulocytes DNA available at time of diagnosis
  • Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
  • Patients with less than 2 years' follow-up
  • For the 10 subjects in NMP :
  • Patients with hematological malignancy and/or solid cancer
  • Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling

Key Trial Info

Start Date :

December 15 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06022328

Start Date

December 15 2023

End Date

December 1 2025

Last Update

July 30 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU de Bordeaux, service Hématologie Biologique

Bordeaux, France